By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


INSYS Therapeutics 

10220 South 51st Street
Suite 2
Phoenix  Arizona  85044  U.S.A.
Phone: 602-910-2617 Fax: 602-910-2627


Company News
INSYS Initiates Hunt for a New CEO 9/21/2016 6:48:08 AM
Attorney General Accuses INSYS of Deceptively Marketing and Selling Its Opioid Painkiller 8/26/2016 7:28:36 AM
INSYS Reports Phase III Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-To-Severe Postoperative Pain After Bunionectomy 8/24/2016 7:47:26 AM
INSYS Announces First Patient Enrolled In Phase II Trial For The Treatment Of Cocaine Dependence Using Pharmaceutical Cannabidiol 8/18/2016 8:09:45 AM
INSYS Reports Second Quarter 2016 Results 8/3/2016 10:53:20 AM
INSYS To Report Second Quarter 2016 Results 7/20/2016 3:27:25 PM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
FDA Clears INSYS' Syndros 7/5/2016 6:04:51 AM
Three Biotechs Face Near-Term FDA Decisions 3/21/2016 6:36:23 AM
USPTO Declines To Institute All Inter Partes Review Petitions Filed By CFAD Of INSYS U.S. Patents Directed To SUBSYS (Fentanyl Sublingual Spray) 3/10/2016 8:45:21 AM